TGFB1 and synucleinopathy: The alignment between our in vitro results and the published observations in human post-mortem brains as well as vCSF of PD patients [46, 47], supports our findings and thus could be the basis for the development of TGFb-inhibiting drugs as therapeutic approach for PD and related synucleinopathies.